On 26 June, the European Medicines Agency (EMA) Working Parties with Patients’ and Consumers’ Organisations (PCWP) and Healthcare Professionals’ Organisations (HCPWP) held a virtual meeting with all EMA eligible organisations. More than 50 attendees joined the meeting.
An update on the relocation of the agency from London to Amsterdam and Brexit preparedness were provided to meeting delegates. During the meeting, the group discussed about the new mandate 2019-2022. June 2019 marks the start of the new mandate for both the PCWP and HCPWP. The working parties are composed of the following members: selected patient/ consumer, healthcare professional organisations that fulfil EMA eligibility criteria, scientific committees, EMA secretariat and observers. We were pleased to hear that the group is planning to reconvene face to face meetings in September 2019 in Amsterdam. In addition, the group pointed out the new mandate 2019-2022 and highlighted four key areas of work including: 1) medicines development and evaluation, 2) information on medicines, 3) building trust and developing methodology and 4) public focus health area. Other topics discussed during the meeting included Patient-Reported Outcomes in scientific advice study and the protection of personal data within EMA. Cindy Birck represented Alzheimer Europe, a full member of the PCWP, at the meeting.
On 24 May, Alzheimer Europe received a positive outcome from a periodic EMA re-evaluation of eligibility. The letter states that AE “has been accepted as member of the PCWP group for the term 2019 to 2022”. AE is delighted to continue its collaboration within the PCWP and look forward to its active involvement over the next mandate of the group.
